Venous thromboembolism (VTE) is a major cause of morbidity and mortality in cancer patients. In a large population-based cohort study from Denmark, the VTE incidence within the first 6 months after cancer diagnosis has been shown to significantly increase between 1997 and 2017 [1]. Acute leukemias are prothrombotic diseases, which is attributed to the induction of leukemic cell procoagulant activity, especially following treatment-mediated leukemia cell death [2,3]. Catheter-related thrombosis (CRT), defined as VTE associated with central venous catheters (CVCs), may occur shortly after catheter insertion [4] and its incidence varies between 3.0 and 11.7%, depending on the leukemia subtype [5,6].
